Kronos Bio, a San Mateo, Calif. & Cambridge, Mass.-based company dedicated to the discovery and development of first-in-class therapies that modulate historically undruggable targets, closed a $105m Series A financing.
The round was led by Vida Ventures and Omega Funds with participation from Nextech, GV (formerly Google Ventures), Perceptive Advisors, Invus, Polaris Partners, Kronos President and Chief Executive Officer Norbert Bischofberger, Ph.D. as well as members of the Board of Directors Arie Belldegrun, M.D., FACS and John Martin, Ph.D.
In conjunction with this financing, Jakob Loven, Ph.D., Partner at Nextech, will join the Board of Directors of Kronos Bio.
Built on more than a decade of research by its scientific founder, Angela Koehler, Ph.D., Associate Professor of Biological Engineering at the Massachusetts Institute of Technology, Kronos Bio is dedicated to the discovery and development of first-in-class therapies that modulate historically undruggable targets. It leverages deep capabilities in high-throughput small molecule microarrays, targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.
SMM is ideally suited for the rapid discovery of novel modulators or degraders of historically undruggable targets, such as transcription factors.
Kronos is a Two River portfolio company.